Stateside boost to Relenza orders

Published: 4-Jul-2006

The United States Department of Health and Human Services (HHS) has stated that it will increase its stockpile of the anti-viral treatment Relenza by 12.3 million courses.


The United States Department of Health and Human Services (HHS) has stated that it will increase its stockpile of the anti-viral treatment Relenza by 12.3 million courses.

The HHS intends to have a stockpile of 81 million courses of the drug by the completion date, December 2008. By December 2006 HHS will have a stockpile of 26 million courses of Relenza.

Peter Cook, CEO of the Australian pharmaceutical firm Biota who develop and manufacture Relenza, described the additional orders as "welcome news".

You may also like